Second-Line Paclitaxel Effective in Advanced NSCLC
TOKYO-Weekly paclitaxel (Tax-ol) and carboplatin (Paraplatin) is an effective and well-tolerated second-line therapy in patients with non-small-cell lung cancer (NSCLC) who failed first-line therapy with the same agents, Mark A. Socinski, MD, said at the 9th World Conference on Lung Cancer. Dr. Socinski is director of the Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill.
TOKYOWeekly paclitaxel (Tax-ol) and carboplatin (Paraplatin) is an effective and well-tolerated second-line therapy in patients with non-small-cell lung cancer (NSCLC) who failed first-line therapy with the same agents, Mark A. Socinski, MD, said at the 9th World Conference on Lung Cancer. Dr. Socinski is director of the Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill.
The 55 patients were first treated on a phase III trial designed to address the optimal duration of first-line paclitaxel/carboplatin. They were then split into three groups: (1) patients with refractory NSCLC who progressed after two cycles of first-line therapy, (2) patients who received four cycles of first-line therapy and were then observed until progression, and (3) patients who received continuous chemotherapy until progression.
Median survival from the start of second-line therapy was 6.6 months for all patients, with 1-year survival of 24%, Dr. Socinski said. Overall survival was affected by initial disease sensitivity with median survival for groups 1, 2, and 3 of 5.2, 10.0, and 5.3 months, respectively. The overall response rate to second-line therapy was 9%. There was no significant decrease in quality of life over the first 5 weeks of second-line therapy.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025